Skip to main content

Table 1 Baseline and endpoint assessments in completers in the TACIT and CARDERA trials (mean scores (95 % confidence intervals))

From: Optimal responses in disease activity scores to treatment in rheumatoid arthritis: Is a DAS28 reduction of >1.2 sufficient?

EULAR Response

Number

DAS28

HAQ

EQ5D

  

Initial

Endpoint

Initial

Endpoint

Initial

Endpoint

CARDERA trial

None

121

5.45 (5.22, 5.68)

5.67 (5.45, 5.89)

1.43 (1.30, 1.56

1.53 (1.39, 1.67)

0.46 (0.40, 0.51)

0.48 (0.43, 0.53)

Moderate

160

6.08 (5.89, 6.27)

4.21 (4.07, 4.35)

1.70 (1.60, 1.80)

1.31 (1.20, 1.42)

0.42 (0.37, 0.46)

0.60 (0.56, 0.63)

Good

98

5.57 (5.33, 5.80)

2.17 (2.04, 2.30)

1.47 (1.35, 1.60)

0.60 (0.48, 0.72)

0.47 (0.42, 0.52)

0.77 (0.73, 0.80)

TACIT trial

None

34

6.40 (6.08, 6.71)

6.34 (6.06, 6.63)

2.15 (2.00, 2.29)

2.11 (1.94, 2.28)

0.22 (0.11, 0.33)

0.23 (0.13, 0.34)

Moderate

86

6.30 (6.11, 6.49)

4.23 (4.07, 4.38)

1.91 (1.78, 2.04)

1.58 (1.42, 1.73)

0.41 (0.35, 0.47)

0.56 (0.51, 0.61)

Good

66

6.13 (5.96, 6.30)

2.29 (2.14, 2.44)

1.64 (1.47, 1.81)

1.00 (0.81, 1.19)

0.40 (0.32, 0.47)

0.69 (0.64, 0.75)

  1. TACIT tumour necrosis factor inhibitors against combination intensive therapy, CARDERA cost-effectiveness of treatment strategies using combination of disease modifying anti-rheumatic drugs and glucocorticoids in early rheumatoid arthritis, EULAR European League Against Rheumatism, DAS28 twenty-eight joint disease activity score, HAQ Health Assessment Questionnaire, EQ5D Euroqol-5D